October 30, 2020
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
Member/Center Highlights
Cancer-focused Summer Undergraduate Research (CanSUR) Program to open applications for 2021 scholars November 1
Launched in 2019, the Cancer-focused Summer Undergraduate Research Program, CanSUR, supports 32 undergraduates for a 10-week period (June through August) each summer. Undergraduates will be accepted from colleges and universities from across the country to work with one of 82 Case Comprehensive Cancer Center (Case CCC) researchers.

This year, 32 exceptional undergraduates from over 200 applications and 77 schools were selected for the program, but in the interest of public safety in the face of the pandemic, the summer 2020 program was canceled.

The Case Comprehensive Cancer Center's Office of Cancer Training, Education and Research is hopeful that the 10-week summer program for 2021 will take place and will begin accepting applications on November 1.

Questions about CanSUR? Please contact Education Program Manager Gena Richmann at gnb15@case.edu.
Madabhushi selected for newly-formed Aiforia Scientific Advisory Board
Anant Madabhushi, PhD was recently selected as one of four members to serve on the Scientific Advisory Board of Aiforia, provider of deep learning artificial intelligence (AI) solutions for medical image analysis. The board will support Aiforia's mission in providing the most powerful tools for AI-assisted analysis to enhance the translation of medical images into data and discoveries in all realms of healthcare.

Dr. Madabhushi is the Donnell Institute Professor of Biomedical Engineering at Case Western Reserve University, Director of the Case Center for Computational Imaging and Personalized Diagnostics (CCIPD) and member of the Case Comprehensive Cancer Center's Cancer Imaging Program.
Monday's Expert Panel: Addressing Systemic Structural Problems in STEM
Join the Office of the Provost on Monday, November 2 at 1 pm for an expert panel focused on highlighting approaches and strategies that can help Case Western Reserve address systemic structural problems in the STEM disciplines. Panelist presentations will be followed by a robust question and answer period via live video and the Zoom chat feature, moderated by Provost Ben Vinson. The intent of this session is to help CWRU realize Pathway 4 of its Think Big strategic plan to build a respectful, diverse and effective university community and become a campus that truly reflects its students, city, and country.

Later, panelists will engage one-on-one with representative faculty, postdoctorates and graduate students in order to get a sense of the current culture. Panelists will then provide an executive summary of their observations to be shared with university leadership. This will help build a baseline of understanding for our growth and development as a university.

Panelists include:
Alison K. Hall, PhD
Associate Dean for Research Workforce Development
School of Medicine and Health Sciences
George Washington University
Clifton Poodry, PhD
Courtesy Professor
University of Oregon
Michael F. Summers, PhD
Robert E. Meyerhoff Chair for Excellence in Research and Mentoring
Distinguished University Professor
University of Maryland, Baltimore County
UH and CWRU announce study of AstraZeneca's COVID-19 vaccine candidate
University Hospitals (UH) and Case Western Reserve University (CWRU) announced yesterday that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca. The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. UH is part of the NIAID-supported COVID-19 Prevention Network (CoVPN). UH will study AZD1222 as one of approximately 80 clinical investigational sites in the U.S. that will collectively enroll up to 30,000 participants.
Watch: Dr. Hill on the Impact of the COVID-19 Pandemic in MCL
Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician at Cleveland Clinic Taussig Cancer Institute, assistant professor of hematology and oncology and member of the Case Comprehensive Cancer Center, discusses the impact of the COVID-19 pandemic on patients with mantle cell lymphoma (MCL) with OncLive.
Case CCC COVID-19 Resource Hub
The Case Comprehensive Cancer Center (Case CCC) has centralized COVID-19 related news, resources and funding opportunities for our cancer center community. Content is updated regularly.

To have a cancer-focused resource added to the page, please email cancer@case.edu.
What's Coming Up
Mark Your Calendar
Cancer Center Seminar Series
Friday, October 30, 2020, 12p via Zoom
Today's Cancer Center Seminar welcomes Trevor Archer, PhD presenting, "Diversity and Heterogeneity in Chromatin and Transcription" at noon via Zoom.

Dr. Archer is an NIH Distinguished Investigator and Chief of the Epigenetic & Stem Cell Biology Laboratory (ESCBL) at the National Institute of Environmental Health Sciences, National Institutes of Health.

The long-term goals of Dr. Archer’s research are to understand the mechanisms by which gene transcription is altered during development and in disease states, focusing principally on breast cancer and the impact of environmental factors in these processes. To realize these goals, Dr. Archer has used embryonic stem cells and breast cancer cell lines as model systems to study the mechanisms that govern regulated transcription from mammalian genes in response to endogenous and exogenous signals. Because of their widespread use in endocrine therapy, his lab’s work has placed an emphasis on the mode of action of steroid hormone receptors in response to natural ligands, as well as synthetic agonists and antagonists. He has paid particular attention to the principles that permit the modulation of transcriptional responses via sequence specific binding of transcription factors. In this area, his research team has extensively studied the potential regulatory role of chromatin architecture in modulating the activity of these transcriptional effectors.
Cancer Center Seminar Series
Friday, November 6, 2020, 12p via Zoom

Next week's Cancer Center Seminar features guest speaker Jennifer Adair, PhD presenting, "Delivering on the Promise of Gene Therapy: Translating Accessible Treatments," virtually at 12 pm ET.

Dr. Adair is Associate Professor, Stem Cell and Gene Therapy Program, Clinical Research Division at Fred Hutchinson Cancer Research Center. She is also Research Associate Professor in the Department of Medical Oncology at University of Washington and holds the Fleischauer Family Endowed Chair in Gene Therapy Translation.

She joined Fred Hutch in 2008 where she translated multiple clinical trials for blood stem cell gene therapy for diseases including glioblastoma, Fanconi’s anemia, primary immunodeficiencies and HIVunder Dr. Hans-Peter Kiem. She transitioned to faculty in 2013 andis currently an Associate Professor in the Stem Cell and Gene Therapy Program at Fred Hutch and a Research Associate Professor in Medical Oncology at the University of Washington.The ultimate goal of her laboratory is to develop new clinical methods and technologies to make gene therapy affordable and accessible to patients worldwide. Jennifer was named an Outstanding New Investigator by the American Society of Gene and Cell Therapy, where she serves as an elected Board Member. Her lectures have been featured by TEDx, GeekWire and AAAS. In 2020, Jennifer was honored as the Fleischauer Family Endowed Chair in Gene Therapy Translation. She has more than 40 peer-reviewed publications and is an inventor on seven patents.
Multidisciplinary Colorectal Oncology Course
November 6, 2020, 9a-12:30p
This symposium will focus on providing an in-depth and up-to-date review of the multidisciplinary management of colorectal cancers.

Oncologists, surgeons, radiation oncologists and nurses with an interest in the management of patients with colorectal cancer should participate in this course.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™.
Biomedical Graduate Student Symposium (Virtual)
November 9-10, 2020
The Biomedical Graduate Student Symposium (BGSS) is a student-run event that celebrates student research in the School of Medicine at CWRU. This event will consist of student poster presentations, student oral presentations, and a keynote address from Dr. Yasmine Belkaid, National Institute of Allergy and Infectious Diseases (NIAID). BGSS will also partner with the Career Opportunities for Trainees Series (COTS) for a career panel (details and panelists to be announced).

Contact casebgss@gmail.com with any questions or concerns.
Additional Upcoming Events
NCCN 2021 Virtual Annual Conference: Call for Abstracts
Abstract Deadline: November 11, 2020
NCCN is now accepting abstracts for consideration to be presented during the NCCN 2021 Annual Conference General Poster Session to be held virtually Thursday, March 18 through Saturday, March 20, 2021. NCCN welcomes original abstracts from investigators in the general oncology community. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate.

Research may fall into the general areas below:

  • Clinical Oncology (all phases)
  • Pre-Clinical Oncology
  • Epidemiology/Risks/Prevention
  • Correlative/Genomic
  • Best Practices in Implementation and Use of Clinical Practice Guidelines
  • Quality Improvement
  • Outcomes and Health Services Research
  • Bioinformatics/Information Technology Sciences
Sixth Computational Approaches for Cancer Workshop (CAFCW20)
Workshop: November 13, 2020
The National Cancer Institute Center for Biomedical Informatics and Information Technology and SC20 are seeking abstracts for presentations for the Sixth Computational Approaches for Cancer Workshop (CAFCW20). CAFCW20 is a workshop designed to bring together clinicians, cancer biologists, mathematicians, data scientists, computational scientists, engineers, developers, thought leaders, and anyone else interested in advancing computation to use in cancer care and research. This year’s topic is “AI and HPC: Overcoming Data Challenges in Cancer Research and Clinical Applications.”

A special emphasis for the CAFCW20 is the role of HPC and AI to address research challenges when data are limited by availability, variability and size. The workshop will be held in conjunction with SC20: The International Conference on High Performance Computing, Networking, Storage and Analysis in Atlanta, GA., on November 15.
Upcoming Policy Forums: Cost of Cancer, Tobacco
November 16 and November 19, 2020
More than 70,000 Ohioans will be diagnosed with cancer in 2020 and the decisions made in the statehouse or in the White House can be just as consequential for patients as the decisions made in their doctor’s office.

Join the American Cancer Society Cancer Action Network (ACS CAN) for a virtual, wide-ranging discussion about the public policies that affect the cost of, access to and delivery of cancer treatment on Monday, November 16 at 11:00 am. Register for the Virtual Cancer Policy Forum: The Cost of Cancer in Ohio.

On Thursday, November 19 at 11:30 am, ASC CAN is hosting the annual Northern Ohio Policy Forum, bringing together leaders from business, education, government and research communities. The 2020 event will discuss the toll of tobacco. Register for the 2020 Northern Ohio Policy Forum: The Toll of Tobacco.
NCCN Virtual Patient Advocacy Summit
December 10, 2020
Patients with cancer often have widely divergent care experiences from screening through survivorship. Differences in care delivery and outcomes may be due, in part, to varying patient needs and preferences according to age and stage of life; inconsistent implementation of guidelines, recommendations, and policies; and unintended age bias in health care. The National Comprehensive Cancer Network’s® (NCCN®) Virtual Patient Advocacy Summit will provide an opportunity for a varied group of stakeholders including patients, caregivers, providers, patient advocacy organizations, policymakers, and industry to thoughtfully discuss the importance of providing quality, effective, efficient, and accessible cancer care across the patient lifespan.
SGO 2021 Annual Meeting
EXTENDED ABSTRACT DEADLINE: November 6, 2020
Annual Meeting: March 20-23, 2021
The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer is a comprehensive forum for the subspecialty of gynecologic oncology. Whether you’re a physician, surgeon, researcher, allied health professional or a student in the field, you can join us to make the connections that will boost your career, see what’s new in gynecologic oncology science and research, and learn the best practices and techniques that can take your care to the next level.

The Call for Abstracts and Surgical Films for the SGO 2021 Annual Meeting on Women’s Cancer has been extended through November 6, 2020. Call for Late-breaking abstracts will be open December 1, 2020 through January 4, 2021.
Funding Opportunities
LOI Deadline: November 9, 2020
Full Application Deadline: November 23, 2020
The Case Comprehensive Cancer Center, with funds from its American Cancer Society Institutional Research Grant, will provide seed money to foster cancer research by junior faculty who have no current national grant support of their own. Investigators in the CWRU School of Medicine, University Hospitals of Cleveland, and Cleveland Clinic Lerner College of Medicine as well as in other schools and colleges affiliated with Case Western Reserve University are eligible. Grants, not to exceed $40,000, will be awarded to investigators who intend to gather preliminary data to be used in seeking future and independently funded programs.

Award Description
  • Pilot funding for cancer-related research with a basic, clinical, prevention & control, behavioral, health services, or epidemiological focus.
  • Up to $40,000 award
  • Grants will be awarded to junior investigators who intend to gather preliminary data to be used in seeking future and independently funded programs

Postdoctoral fellows, graduate students, research associates, and instructors within another PI’s laboratory are not eligible to apply for these research grants. The subject of the proposed research must be directly related to cancer. The principal investigator must be a full-time member of the faculty within 6 years of their first full-time independent faculty appointment (or equivalent).

The Case Comprehensive Cancer Center has been invited to nominate one investigator for the V Scholar Grant for Black/African American Cancer Researchers. This grant opportunity will be specifically for researchers who come from the Black/African American community, a minority group that is underrepresented in the scientific community. The V Scholar Award supports early tenure-track faculty by funding a range of projects from laboratory-based fundamental research through bench to bedside research. The total amount of the grant is $200,000, paid in two annual installments of $100,000. Only direct costs of the research are supported by this award.

SPECIAL FOCUS AREA: ANY area of adult cancer research.


Application Information
Submit a one-page specific aims response and biosketch by Tuesday, November 10, 2020 to casecccpilots@case.edu.
Deadline: December 1, 2020
The Case Comprehensive Cancer Center requests applications for Cancer Data Sciences pilot projects. Cancer Data Sciences will serve as a discipline in the Case CCC to standardize and organize data for optimal use and leverage advanced analytic approaches to enable independent and synergistic research for basic, clinical, population and translation sciences. Pilot applications should focus on driving new analytical capabilities, developing novel algorithms in order to mine, organize, and standardize cancer data as well as utilizing data sciences approaches to extract knowledge from complex, multi-level cancer data for maximal impact.

Award Description
  • Four (4) awards each at a maximum of $45,000, for one year will be awarded, with the potential for a second year dependent on progress. 
  • Metrics and Milestones will be: novel algorithms to be disseminated to Cancer center members, standardized datasets to be available to Cancer center members, peer-reviewed publications, peer-reviewed meeting presentations and/or generation of pilot data for peer-reviewed funding. 
  • Open to Case Comprehensive Cancer Center members. 
AACR
The AACR-Bristol Myers Squibb Midcareer Female Investigator Grant represents a joint effort to encourage and support mid-career female physician-scientists and researchers to conduct immuno-oncology research and to foster their career advancement toward becoming a senior investigator. Research projects may be translational and/or clinical in nature with a focus on immuno-oncology.

The grant provides $225,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators, postdoctoral or clinical research fellows, graduate students, and/or research assistants; research/laboratory supplies; equipment; publication charges for manuscripts that pertain directly to the funded project; and other research expenses (indirect costs are not permitted).

Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants must also have received their first NIH R01 (or equivalent) award within the past 10 years (i.e., grant cannot have been awarded before July 1, 2011).
Doris Duke Charitable Foundation
Deadline: January 5, 2021 at 3 pm ET

The Doris Duke Physician Scientist Fellowship program provides grants to physician scientists at the subspecialty fellowship level who are seeking to conduct additional years of research beyond their subspecialty requirement. The goal is to aid in the transition into a research faculty appointment.
The Physician Scientist Fellowship consists of $100,000 for annual direct costs plus $10,000 (10%) for annual indirect costs for two years. The priority of the Physician Scientist Fellowship program is to fund outstanding individuals with excitement for clinical research careers, whose projects will address highly significant research questions and lead to career advancement. DDCF does not have funding priorities for this fellowship based on disease area or research type. In keeping with the wishes expressed in Doris Duke's will, experiments that use animals or tissues derived from animals, including cell lines, are not supported by this program.
In The News
Mirage News - October 13, 2020
 A team of two Case Western Reserve University School of Medicine faculty members and two students developed COVID-19 Predict, an intuitive, dynamic tool to monitor viral transmission across the U.S. Featuring maps with a simple, color-coded key, the dashboard can help people understand risks within their community and plan accordingly.
Elemental - October 19, 2020
Mark Cameron, PhD associate professor at the School of Medicine and member, Case CCC, shared concerns about when the rate of new infections ratchets up from linear to exponential—doubling every few days instead of every few weeks.
From The NIH
Weekly NIH Funding Opportunities and Notices
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.